1875-Breast trastuzumab subcutaneous

Trastuzumab and pertuzumab trastuzumab Interpretation We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early trastuzumab In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast

trastuzumab Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 -positive breast cancer and